There is another ongoing phase I trial of PD-L1-based vaccinations in multiple myeloma [210], in which a combination of IDO and PD-L1-specific T cell vaccinations with nivolumab is employed for metastatic melanoma [211]. This evidence concerns the gene CD274 and plasma cell myeloma.